Literature DB >> 15747040

Self-management of oral anticoagulation in nonvalvular atrial fibrillation (SMAAF study).

H Völler1, J Glatz, U Taborski, A Bernardo, C Dovifat, K Heidinger.   

Abstract

UNLABELLED: Most patients with atrial fibrillation are at risk of suffering thromboembolic events. This risk can be reduced by twothirds by efficient anticoagulation. This prospective multi-center trial investigated whether the quality of treatment can be improved by self-management in patients with atrial fibrillations (SMAAF Study) compared to conventional patient management by the family doctor.
METHODS: Two thousand patients suitable for self-management were to be randomized into the two arms of the study. In the period of investigation from December 1999 to July 2001, only 202 patients (64.3+/-9.2 years, 69.3% men) consented to participate. The study was discontinued prematurely since the number of patients was too low. As a consequence, the group comparison is confined to the evaluation of the INR values measured using the two-tailed t test.
RESULTS: Of the 202 patients included, 101 were assigned to the self-management group (64.6+/-9.6 years, 71.4% men) and 101 (64.1+/-8.9 years, 61.4% men, n.s.) were assigned to the group managed by the family doctor. The total number of INR measurements was 2 865. This comprised 2 072 measurements in patients under self-management and 793 in the family doctor group. The values were within the target range significantly more frequently (p=0.0061) in patients under self-management (67.8%) as compared to the family doctor group (58.5%). There was a trend with regard to the time within target range, but the difference was not significant (178.8+/-126 days as compared to 155.9+/-118.4 days). In the self-management group, there were two severe hemorrhages, and there was one thromboembolic event in the family doctor group.
CONCLUSION: Management of oral anticoagulation by INR self-management in patients with atrial fibrillation is not inferior to conventional care.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15747040     DOI: 10.1007/s00392-005-0199-0

Source DB:  PubMed          Journal:  Z Kardiol        ISSN: 0300-5860


  28 in total

1.  Clinical outcome of self-management of oral anticoagulation in patients with atrial fibrillation or deep vein thrombosis.

Authors:  K S Heidinger; A Bernardo; U Taborski; G Müller-Berghaus
Journal:  Thromb Res       Date:  2000-05-15       Impact factor: 3.944

Review 2.  [Recommendations for prevention of thromboembolism in elderly internal medicine patients].

Authors:  K Rossol-Haseroth; C U Vogel; F Reinecke; H Burkhardt; Ch Heun-Letsch; B Wieth; A Peiter; U Heinrich; I Jörg; H Völler; B Kemkes-Matthes; T K Nordt; H C Diener; M Gehrlein; R Gladisch; M Wehling; J Harenberg
Journal:  Internist (Berl)       Date:  2002-09       Impact factor: 0.743

3.  A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation.

Authors:  Isabelle C Van Gelder; Vincent E Hagens; Hans A Bosker; J Herre Kingma; Otto Kamp; Tsjerk Kingma; Salah A Said; Julius I Darmanata; Alphons J M Timmermans; Jan G P Tijssen; Harry J G M Crijns
Journal:  N Engl J Med       Date:  2002-12-05       Impact factor: 91.245

4.  Interobserver agreement for the assessment of handicap in stroke patients.

Authors:  J C van Swieten; P J Koudstaal; M C Visser; H J Schouten; J van Gijn
Journal:  Stroke       Date:  1988-05       Impact factor: 7.914

5.  [Neurological events in patients with atrial fibrillation: outcome and preventive practices].

Authors:  J Carlsson; S Miketic; E Flicker; A Erdogan; S Haun; A Cuneo; U Tebbe
Journal:  Z Kardiol       Date:  2000-12

6.  Coronary heart disease and atrial fibrillation: the Framingham Study.

Authors:  W B Kannel; R D Abbott; D D Savage; P M McNamara
Journal:  Am Heart J       Date:  1983-08       Impact factor: 4.749

7.  Oral anticoagulation and hemorrhagic complications in an elderly population with atrial fibrillation.

Authors:  M Copland; I D Walker; R C Tait
Journal:  Arch Intern Med       Date:  2001-09-24

8.  Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy.

Authors:  G Palareti; N Leali; S Coccheri; M Poggi; C Manotti; A D'Angelo; V Pengo; N Erba; M Moia; N Ciavarella; G Devoto; M Berrettini; S Musolesi
Journal:  Lancet       Date:  1996-08-17       Impact factor: 79.321

9.  Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischemic stroke and atrial fibrillation in the International Stroke Trial.

Authors:  R Saxena; S Lewis; E Berge; P A Sandercock; P J Koudstaal
Journal:  Stroke       Date:  2001-10       Impact factor: 7.914

10.  Assessment of a bleeding risk index in two cohorts of patients treated with oral anticoagulants.

Authors:  F J van der Meer; F R Rosendaal; J P Vandenbroucke; E Briët
Journal:  Thromb Haemost       Date:  1996-07       Impact factor: 5.249

View more
  15 in total

1.  An evaluation of patient self-testing competency of prothrombin time for managing anticoagulation: pre-randomization results of VA Cooperative Study #481--The Home INR Study (THINRS).

Authors:  Rowena J Dolor; R Lynne Ruybalid; Lauren Uyeda; Robert G Edson; Ciaran Phibbs; Julia E Vertrees; Mei-Chiung Shih; Alan K Jacobson; David B Matchar
Journal:  J Thromb Thrombolysis       Date:  2010-10       Impact factor: 2.300

2.  Cost-effectiveness of self-managed versus physician-managed oral anticoagulation therapy.

Authors:  Dean A Regier; Rubina Sunderji; Larry D Lynd; Kenneth Gin; Carlo A Marra
Journal:  CMAJ       Date:  2006-06-20       Impact factor: 8.262

Review 3.  Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation.

Authors:  Danielle E Clarkesmith; Helen M Pattison; Phyo H Khaing; Deirdre A Lane
Journal:  Cochrane Database Syst Rev       Date:  2017-04-05

4.  Patient self-management of warfarin therapy: pragmatic feasibility study in Canadian primary care.

Authors:  Brian E Grunau; Matthew O Wiens; Kenneth K Harder
Journal:  Can Fam Physician       Date:  2011-08       Impact factor: 3.275

5.  American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy.

Authors:  Daniel M Witt; Robby Nieuwlaat; Nathan P Clark; Jack Ansell; Anne Holbrook; Jane Skov; Nadine Shehab; Juliet Mock; Tarra Myers; Francesco Dentali; Mark A Crowther; Arnav Agarwal; Meha Bhatt; Rasha Khatib; John J Riva; Yuan Zhang; Gordon Guyatt
Journal:  Blood Adv       Date:  2018-11-27

Review 6.  Self-monitoring and self-management of oral anticoagulation.

Authors:  Carl J Heneghan; Josep M Garcia-Alamino; Elizabeth A Spencer; Alison M Ward; Rafael Perera; Clare Bankhead; Pablo Alonso-Coello; David Fitzmaurice; Kamal R Mahtani; Igho J Onakpoya
Journal:  Cochrane Database Syst Rev       Date:  2016-07-05

Review 7.  Self-management of oral anticoagulation.

Authors:  Andrea Siebenhofer; Klaus Jeitler; Karl Horvath; Wolfgang Habacher; Louise Schmidt; Thomas Semlitsch
Journal:  Dtsch Arztebl Int       Date:  2014-02-07       Impact factor: 5.594

8.  Safety and effectiveness of point-of-care monitoring devices in patients on oral anticoagulant therapy: a meta-analysis.

Authors:  Philip S Wells; Allan Brown; James Jaffey; Lynda McGahan; Man-Chiu Poon; Karen Cimon
Journal:  Open Med       Date:  2007-10-16

Review 9.  Is self-monitoring an effective option for people receiving long-term vitamin K antagonist therapy? A systematic review and economic evaluation.

Authors:  Pawana Sharma; Graham Scotland; Moira Cruickshank; Emma Tassie; Cynthia Fraser; Christopher Burton; Bernard Croal; Craig R Ramsay; Miriam Brazzelli
Journal:  BMJ Open       Date:  2015-06-25       Impact factor: 2.692

10.  Point-of-Care International Normalized Ratio (INR) Monitoring Devices for Patients on Long-term Oral Anticoagulation Therapy: An Evidence-Based Analysis.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2009-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.